The advent of new orally bioavailable kinase inhibitors will impact shortly on the strategies that we employ in the treatment of rheumatoid arthritis. The position that they occupy in the treatment paradigms will be influenced by their efficacy, safety profile, cost and their ability to combine with other medications related to arthritis treatment and to other co-morbid conditions. This lecture will review their potential value in each of these domains.
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.